{
    "2021-05-03": [
        [
            {
                "time": "2023-10-18",
                "original_text": "High-Yield Stocks for Dividend Investors",
                "features": {
                    "keywords": [
                        "High-Yield",
                        "Stocks",
                        "Dividend",
                        "Investors"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Beovu",
                        "Aflibercept",
                        "Phase 3",
                        "Diabetic Macular Edema"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "ophthalmology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Eli Lilly",
                        "Merck",
                        "GlaxoSmithKline",
                        "Novartis",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Novartis biosimilar targets rivals' Eylea eye treatment",
                "features": {
                    "keywords": [
                        "Novartis",
                        "biosimilar",
                        "Eylea",
                        "eye treatment"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "ophthalmology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine",
                "features": {
                    "keywords": [
                        "Sandoz",
                        "late-stage",
                        "clinical development",
                        "biosimilar",
                        "aflibercept",
                        "ophthalmology"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "ophthalmology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}